Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The story of multiple sclerosis: 1838-1993
- The symptoms of multiple sclerosis
- Pathogenesis of MS
- Pathogenesis of MS: possible therapies
- Pathological hetrogeneity in MS
- Impairment of function and the MS clinical course
- Reduced MS activity with interferon-beta-1b
- Pivotal trials in relapsing-remitting MS (1)
- Pivotal trials in relapsing-remitting MS (2)
- Cochrane analysis of interferon efficacy
- Monoclonal antibody trialed in MS
- Pivotal trials of ZENAPAX (daclizumab): results
- Nataluzimab\tysabru reduces relapse rate
- Pivotal trials of tysabri - 2 year results
- PML with tysbari
- The story of Campath-1H treatment
- Campath-1H causes prolonged T-cell depletion
- Effects of the first dose of Campath-1H
- Axonal damage is caused before conduction block
- Campath-1H suppresses relapses in MS
- Effect of Campath-1H on disability
- Comparison of trials on Campath-1H and tysbari
- Infections after Campath-1H
- Graves' disease after Campath-1H treatment ( 1)
- Graves' disease after Campath-1H treatment (2)
- Immune trombocytopenia after Campath-1H
- Autoimmune disease after Campath-1H
- Other examples of reconstitution autoimmunity
- Pathology and course of MS
- Treatment of MS - 2006 and beyond
Topics Covered
- The story of multiple sclerosis
- Symptoms
- Pathogenesis
- Pathological heterogeneity
- Axonal degeneration
- Current treatments
- Interferons and glatiramer
- Monoclonal antibody treatment of multiple sclerosis
- Daclizumab
- Natalizumab
- The story of Campath-1H
- The effect of Campath-1H on disability depends upon the stage of the disease
- Graves' disease
- Immune thrombocytopenia
- Future treatment of multiple sclerosis
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Coles, A. and Compston, A. (2007, October 1). Antibody therapy of multiple sclerosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/KLCK1482.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Alasdair Coles has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Prof. Alastair Compston has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.